• Home
  • About Journal
    Journal Introduction
    Editorial Board
    Youth Editorial Board
    Cooperating Institutions
    Editorial Department
  • Submission Guidelines
  • Policies & Statements
    Ethical Guidelines for Publication
    Academic Misconduct Statement
    Open Access (OA) Statement
    AIGC Use Statement
  • Journal Subscription
  • Download Center
  • 中文版
Cite this article:
FENG Hui,GAO Feng,WANG Haoming,WANG Wenhua,LIU Lianhua,LIU Qingtao,HUANG Bingjian.Clinical observation of PEG-rhG-CSF secondary prevention on hematological toxicity caused by whole brain and spinal cord radiotherapy[J].Journal Of Pharmaceutical Research,2021,40(1):56-59[Click to copy]
【Print this page】      【Download PDF Full Text】   【View/Add Comment】  【Download reader】  【 Close 】
←Previous|Next→ Archive    Advanced Search
This article has been viewed: 2677times   Download 2446次 QR Code for this article
Scan with your phone!
PEG-rhG-CSF次级预防对全脑全脊髓放疗致血液学毒性的临床疗效观察
冯会,高峰,王浩铭,王文华,刘莲花,刘庆涛,黄丙俭
Font:Larger+|Default|Smaller-
(临沂市肿瘤医院放疗一科,山东 临沂 276000)
摘要:
目的 观察聚乙二醇化重组人粒细胞刺激因子(PEG-rhG-CSF)次级预防在全脑全脊髓放疗过程中对患者血液学毒性的治疗疗效及对放疗疗程的影响。方法 回顾性分析了15例中枢神经系统肿瘤患者在接受全脑全脊髓放疗期间次级预防应用PEG-rhG-CSF对血液学毒性的治疗效果,观察比较性别、年龄、诊断的血液学毒性差异,并探讨了次级预防应用PEG-rhG-CSF对放疗进程的影响。结果 全脑全脊髓放疗期间次级预防应用PEG-rhG-CSF,15例患者中,所有患者均有不同程度的骨髓抑制;其中I度减低有3例(20.0%),Ⅱ度有8例(53.3%),Ⅲ度有2例(13.3%),Ⅳ度有2例(13.3%)。有10例(66.7%)出现血小板减少,其中I度减低的有5例(33.3%),Ⅱ度有3例(20%),Ⅲ度有2例(13.3%),无Ⅳ度减低。5例(33.3%)出现血红蛋白下降,I度的有3例(20.0%),Ⅱ度有2例(13.3%),无Ⅲ度减低。白细胞、血小板、血红蛋白Ⅲ~Ⅳ级骨髓抑制分别为26.7%、13.3%、0.0%。2例 (13.3%)患者因重度血液学毒性中断治疗,中断时间7~8 d,治疗中断的比率为13.3%。次级预防应用PEG-rhG-CSF减少了因血液学毒性引起的放疗暂停的发生。结论 全脑全脊髓放疗出现血液学毒性常见,大部分患者在次级预防应用PEG-rhG-CSF支持下显著减少Ⅲ~Ⅳ级骨髓抑制的发生,从而减少了放疗疗程的延长,保证大部分患者顺利完成了放疗疗程。该方法值得在全脑全脊髓放疗中进一步研究并推广应用。
关键词:  全脑全脊髓照射  聚乙二醇化重组人粒细胞刺激因子  血液学毒性
DOI:10.13506/j.cnki.jpr.2021.01.011
基金项目:
Clinical observation of PEG-rhG-CSF secondary prevention on hematological toxicity caused by whole brain and spinal cord radiotherapy
FENG Hui,GAO Feng,WANG Haoming,WANG Wenhua,LIU Lianhua,LIU Qingtao,HUANG Bingjian
(First Department of Radiotherapy,Linyi Cancer Hospital,Linyi 276000,China)
Abstract:
ObjectiveThe primary goal of this study is to observe the effect brought by secondary prevention with pegylated recombinant human granulocyte-colony stimulating factor (PEG-rhG-CSF) on hematological toxicity and therapy period in whole brain and whole bone marrow radiotherapy.MethodsWe did a rhetorical analysis on 15 patients with tumors on the central neural system (CNS),who were treated with PEG-rhG-CSF for secondary prevention during whole brain and whole bone marrow radiotherapy, to study the effects of such substance on hematological toxicity.Furthermore, we compared the variance in toxicity based on differences in gender,age as well as diagnostic results.Finally,we discussed the outcomes using PEG-rhG-CSF on the radiotherapy during secondary prevention.ResultsWe found that all the 15 patients suffered different degrees of myelosuppression. The corresponding number of patients were 3 (20.0%), 8 (53.3%), 2 (13.3%), 2 (13.3%) for degree I, II, III and IV, respectively. Among the 15 patients, 10 exhibited a decrease in platelet count, where 5 (33.3%), 3 (20%), 2 (13.3%) showed a degree I, II, III decline, respectively. None of them exhibited a degree IV decline in platelets.Additionally,5 of the total 15 patients demonstrated a drop in hemoglobin levels, where 3 of them were degree I and 2 were degree II, with no one suffering degree III decline.Patients showing myelosuppression at degree III or IV as revealed through decreased leukocyte, platelet and hemoglobin levels consisted of 26.7%,13.3% and 0.0% of the total number,respectively.2 patients (13.3%) experienced an interruption, which lasted for 7-8 days, in their treatment due to severe hematological toxicity.Secondary prevention by the application of PEG-rhG-CSF can reduce the interruption resulted from hematological toxicity during radiotherapy.ConclusionIn a word,it is quite common for patients undergoing whole brain and whole bone marrow radiotherapy to exhibit hematological toxicity. With the help of PEG-rhG-CSF during secondary prevention, myelosuppression at degree III or IV is significantly reduced among the majority of such patients, shortening the radiotherapy period and ensuring their completion of the therapy. Therefore, the introduction of PEG-rhG-CSF in secondary prevention is worthy to be further studied and spread for a wider range of applications.
Key words:  Whole brain and whole bone marrow radiotherapy  PEG-rhG-CSF  Blood
Today's Visits:511    Total Visits:2383242
Website copyright:Editorial Board of Journal of Pharmaceutical Research     鲁ICP备17018036号-3     鲁公网安备 37010202001351号
Sponsored by:Shandong Institute for Food and Drug Control Shandong Pharmaceutical Association Address:No.2749 Xinluo Street,High-Tech Zone,Jinan,P.R.China Postcode:250101
Telephone Number:0531-81216586 Email :yaoxueyanjiu@163.com;yaoxueyanjiu@126.com
Technical Support:Beijing Qinyun Technology Co., Ltd.